TG Therapeutics マネジメント

マネジメント基準チェック /24

TG Therapeuticsの CEO はMike Weissで、 Dec2011年に任命され、の在任期間は 12.92年です。の年間総報酬は$ 15.84Mで、 5.5%給与と94.5%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の5.71%を直接所有しており、その価値は€ 274.52M 。経営陣と取締役会の平均在任期間はそれぞれ12.9年と11年です。

主要情報

Mike Weiss

最高経営責任者

US$15.8m

報酬総額

CEO給与比率	5.5%
CEO在任期間	12.9yrs
CEOの所有権	5.7%
経営陣の平均在職期間	12.9yrs
取締役会の平均在任期間	11yrs

経営陣の近況

Recent updates

CEO報酬分析

TG Therapeutics の収益と比較して、Mike Weiss の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Sep 30 2024	n/a	n/a	-US$14m
Jun 30 2024	n/a	n/a	US$96m
Mar 31 2024	n/a	n/a	US$41m
Dec 31 2023	US$16m	US$875k	US$13m
Sep 30 2023	n/a	n/a	-US$26m
Jun 30 2023	n/a	n/a	-US$176m
Mar 31 2023	n/a	n/a	-US$169m
Dec 31 2022	US$10m	US$875k	-US$198m
Sep 30 2022	n/a	n/a	-US$239m
Jun 30 2022	n/a	n/a	-US$288m
Mar 31 2022	n/a	n/a	-US$326m
Dec 31 2021	US$43m	US$1m	-US$348m
Sep 30 2021	n/a	n/a	-US$343m
Jun 30 2021	n/a	n/a	-US$345m
Mar 31 2021	n/a	n/a	-US$319m
Dec 31 2020	US$32m	US$1m	-US$279m
Sep 30 2020	n/a	n/a	-US$231m
Jun 30 2020	n/a	n/a	-US$206m
Mar 31 2020	n/a	n/a	-US$189m
Dec 31 2019	US$13m	US$637k	-US$173m
Sep 30 2019	n/a	n/a	-US$187m
Jun 30 2019	n/a	n/a	-US$159m
Mar 31 2019	n/a	n/a	-US$167m
Dec 31 2018	US$14m	US$656k	-US$173m
Sep 30 2018	n/a	n/a	-US$150m
Jun 30 2018	n/a	n/a	-US$148m
Mar 31 2018	n/a	n/a	-US$132m
Dec 31 2017	US$10m	US$525k	-US$118m

報酬と市場: Mikeの総報酬 ($USD 15.84M ) は、 German市場 ($USD 3.48M ) の同規模の企業の平均を上回っています。

報酬と収益: Mikeの報酬は増加しましたが、会社は利益を上げていません。

CEO（最高経営責任者

Mike Weiss (58 yo)

12.9yrs

在職期間

US$15,837,559

報酬

Mr. Michael S. Weiss, Esq. J.D. also known as Mike, serves as Director of Urica Therapeutics, Inc. He has been an Executive Chairman of Mustang Bio, Inc. since January 2017 and served as its Interim Presid...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Michael Weiss	Chairman	12.9yrs	US$15.84m	5.71% € 274.5m
Sean Power	CFO, Corporate Secretary & Treasurer	12.9yrs	US$1.87m	0.48% € 22.8m
Jenna Bosco	Senior Vice President of Corporate Communications	no data	データなし	データなし
Adam Waldman	Chief Commercialization Officer	6.4yrs	データなし	データなし

12.9yrs

平均在職期間

経験豊富な経営陣: NKB2の経営陣は経験豊富で経験豊富です（平均在職期間は12.9年）。

取締役

名称	ポジション	在職期間	報酬	所有権
Michael Weiss	Chairman	12.9yrs	US$15.84m	5.71% € 274.5m
Laurence Charney	Lead Independent Director	12.6yrs	US$304.70k	0.14% € 6.9m
Kenneth Hoberman	Independent Director	9.9yrs	US$264.70k	0.18% € 8.9m
Yann Echelard	Independent Director	12yrs	US$262.20k	0.16% € 7.5m
Sagar Lonial	Independent Director	4.6yrs	US$259.70k	0.070% € 3.4m
Daniel Hume	Independent Director	9.4yrs	US$262.20k	0.17% € 8.1m

11.0yrs

平均在職期間

58.5yo

平均年齢

経験豊富なボード: NKB2の取締役会は経験豊富で経験豊富です ( 11年の平均在任期間)。

TG Therapeutics マネジメント

マネジメント 基準チェック /24

主要情報

経営陣の近況

Independent Director recently sold €448k worth of stock

Independent Director recently sold €404k worth of stock

Lead Independent Director recently sold €322k worth of stock

CFO, Corporate Secretary & Treasurer recently sold €742k worth of stock

Chairman recently bought €924k worth of stock

Independent Director recently sold €748k worth of stock

Recent updates

Independent Director recently sold €448k worth of stock

Third quarter 2024 earnings released: EPS: US$0.027 (vs US$0.80 in 3Q 2023)

TG Therapeutics, Inc. to Report Q3, 2024 Results on Nov 04, 2024

TG Therapeutics, Inc. Announces Updated Data Presentations Including New Five-Year Data from ULTIMATE I & II Phase 3 Trials Evaluating BRIUMVI (Ublituximab-Xiiy) in Patients with Relapsing Forms of Multiple Sclerosis

Investor sentiment improves as stock rises 18%

TG Therapeutics Receives U.S. Food and Drug Administration Clearance for Its Investigational New Drug (IND) Application

Second quarter 2024 earnings released: EPS: US$0.048 (vs US$0.34 loss in 2Q 2023)

Investor sentiment deteriorates as stock falls 17%

TG Therapeutics, Inc. to Report Q2, 2024 Results on Aug 06, 2024

Independent Director recently sold €404k worth of stock

Los Angeles County Employees Retirement Association Files an Exempt Solicitation Statement with Securities and Exchange Commission

CalSTRS Files an Exempt Solicitation Statement to Shareholders of TG Therapeutics

Investor sentiment improves as stock rises 30%

First quarter 2024 earnings released: US$0.073 loss per share (vs US$0.28 loss in 1Q 2023)

TG Therapeutics, Inc. to Report Q1, 2024 Results on May 01, 2024

Lead Independent Director recently sold €322k worth of stock

Full year 2023 earnings released: EPS: US$0.089 (vs US$1.47 loss in FY 2022)

TG Therapeutics, Inc. to Report Q4, 2023 Results on Feb 27, 2024

Forecast breakeven date pushed back to 2024

CFO, Corporate Secretary & Treasurer recently sold €742k worth of stock

Third quarter 2023 earnings released: EPS: US$0.80 (vs US$0.27 loss in 3Q 2022)

TG Therapeutics, Inc. to Report Q3, 2023 Results on Nov 01, 2023

Forecast breakeven date pushed back to 2025

Chairman recently bought €924k worth of stock

Second quarter 2023 earnings released: US$0.34 loss per share (vs US$0.30 loss in 2Q 2022)

TG Therapeutics, Inc. to Report Q2, 2023 Results on Aug 01, 2023

Independent Director recently sold €748k worth of stock

Forecast breakeven date moved forward to 2024

CFO, Corporate Secretary & Treasurer recently sold €1.8m worth of stock

Tg Therapeutics Announces European Commission Approval for Briumvi (Ublituximab-Xiiy) for the Treatment of Relapsing Forms of Multiple Sclerosis in Adults

Tg Therapeutics Announces European Commission Approval for Briumvi (Ublituximab-Xiiy) for the Treatment of Relapsing Forms of Multiple Sclerosis in Adults

First quarter 2023 earnings released: US$0.28 loss per share (vs US$0.51 loss in 1Q 2022)

Insufficient new directors

No longer forecast to breakeven

Full year 2022 earnings released: US$1.47 loss per share (vs US$2.63 loss in FY 2021)

TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of BRIUMVI™ (ublituximab) in Multiple Sclerosis to be Presented at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum

TG Therapeutics Announces Commercial Launch of BRIUMVI™ (ublituximab-xiiy) for the Treatment of Adult Patients with Relapsing Forms of Multiple Sclerosis

Lead Independent Director recently sold €314k worth of stock

Forecast to breakeven in 2025

TG Therapeutics, Inc. Announces FDA Approval of BRIUMVI™ (ublituximab-xiiy)

TG Therapeutics, Inc. to Report Q3, 2022 Results on Nov 10, 2022

Hagens Berman, National Trial Attorneys, Encourages TG Therapeutics Investors with Losses to Contact Firm’S Attorneys Before Sept. 16Th Deadline in Securities Fraud Class Action

TG Therapeutics, Inc. Announces Results from the ULTIMATE I & II Phase 3 Trials of Investigational Ublituximab in RMS

Second quarter 2022 earnings released: US$0.29 loss per share (vs US$0.59 loss in 2Q 2021)

Pomerantz Law Firm Announces the Filing of A Class Action Against TG Therapeutics, Inc

TG Therapeutics Announces FDA Extension of BLA PDUFA Date for Ublituximab to Treat Patients with RMS

First quarter 2022 earnings released: US$0.51 loss per share (vs US$0.69 loss in 1Q 2021)

TG Therapeutics, Inc., Annual General Meeting, Jun 16, 2022

TG Therapeutics, Inc. Announces Voluntary Withdrawal of the BLA/sNDA for U2 to Treat Patients with CLL and SLL

TG Therapeutics, Inc. Announces Data Presentations from the Ultimate I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis Presented At the American Academy of Neurology Annual Meeting

TG Therapeutics Announces Extension of U.S. FDA BLA/sNDA PDUFA Date for Ublituximab Plus UKONIQ® (U2) to Treat Patients with CLL and SLL

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

TG Therapeutics, Inc. Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis Presented at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum

TG Therapeutics, Inc. to Report Q4, 2021 Results on Mar 01, 2022

TG Therapeutics, Inc. Announces Data from the UNITY-CLL Phase 3 Trial Presented At the 63rd American Society of Hematology Annual Meeting

Third quarter 2021 earnings released: US$0.65 loss per share (vs US$0.73 loss in 3Q 2020)

TG Therapeutics Announces Publication of Results from an Integrated Safety Analysis of UKONIQ® (umbralisib) in Blood Advances

TG Therapeutics, Inc. Announces Combination Data Presentations at the XIX International Workshop on Chronic Lymphocytic Leukemia

Second quarter 2021 earnings released: US$0.59 loss per share (vs US$0.47 loss in 2Q 2020)

No longer forecast to breakeven

TG Therapeutics, Inc.(NasdaqCM:TGTX) dropped from Russell 3000E Value Index

TG Therapeutics, Inc. Announces Presentation of Data from the Ultimate I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis At 7th Congress of the European Academy of Neurology

TG Therapeutics, Inc. Announces Data from Phase 1 Study Evaluating TG-1701 as a Monotherapy

TG Therapeutics Announces FDA Acceptance of Biologics License Application for Ublituximab in Combination with UKONIQ® (umbralisib) as a Treatment for Patients with Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

First quarter 2021 earnings released: US$0.69 loss per share (vs US$0.48 loss in 1Q 2020)

TG Therapeutics Announces Publication of Results from the UNITY-NHL Phase 2B Trial Evaluating Umbralisib

TG Therapeutics, Inc. to Present Results from the ULTIMATE I & II Phase 3 Trials Evaluating Ublituximab in Multiple Sclerosis at the American Academy of Neurology 73rd Annual Meeting

Revenue misses expectations

Full year 2020 earnings released: US$2.42 loss per share (vs US$1.96 loss in FY 2019)

マネジメント基準チェック /24